Anti-Amyloid Antibody Clinical Trials

Migration, Crosslink

📖

Anti-Amyloid Antibody Clinical Trials

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-anti-amyloid-antibody-

📖 Wiki Page

therapeutic1616 wordssynced 2026-04-02

Anti-Amyloid Antibody Clinical Trials

Overview

flowchart TD Anti_Amyloid_Antibody_Clinical["Anti-Amyloid Antibody Clinical Trials"] Anti_Amyloid_Antibody_Clinical["Anti-Amyloid"] Anti_Amyloid_Antibody_Clinical -->|"related to"| Anti_Amyloid_Antibody_Clinical style Anti_Amyloid_Antibody_Clinical fill:#81c784,stroke:#333,color:#000 Anti_Amyloid_Antibody_Clinical["table"] Anti_Amyloid_Antibody_Clinical -->|"related to"| Anti_Amyloid_Antibody_Clinical style Anti_Amyloid_Antibody_Clinical fill:#81c784,stroke:#333,color:#000 Anti_Amyloid_Antibody_Clinical["class"] Anti_Amyloid_Antibody_Clinical -->|"related to"| Anti_Amyloid_Antibody_Clinical style Anti_Amyloid_Antibody_Clinical fill:#81c784,stroke:#333,color:#000 style Anti_Amyloid_Antibody_Clinical fill:#4fc3f7,stroke:#333,color:#000

...

Anti-Amyloid Antibody Clinical Trials

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Antibody Clinical Trials</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">[Lecanemab (Leqembi)](/therapeutics/lecanemab)</td>
<td>Soluble Abeta protofibrils</td>
</tr>
<tr>
<td class="label">[Donanemab (Kisunla)](/therapeutics/donanemab)</td>
<td>Amyloid plaques</td>
</tr>
<tr>
<td class="label">[Gantenerumab](/therapeutics/gantenerumab)</td>
<td>Aggregated Abeta (plaques, oligomers)</td>
</tr>
<tr>
<td class="label">Solanezumab</td>
<td>Soluble Abeta monomers</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">CLARITY-AD</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">TRAILBLAZER-ALZ 2</td>
<td>Donanemab</td>
</tr>
<tr>
<td class="label">GRADUATE-1/2</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">A4</td>
<td>Solanezumab</td>
</tr>
<tr>
<td class="label">CLARITY OLE</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Lecanemab (CLARITY-AD)</td>
</tr>
<tr>
<td class="label">Diagnosis</td>
<td>MCI due to AD, mild AD dementia</td>
</tr>
<tr>
<td class="label">Age</td>
<td>50-90 years</td>
</tr>
<tr>
<td class="label">MMSE</td>
<td>22-30</td>
</tr>
<tr>
<td class="label">Amyloid requirement</td>
<td>PET+ or CSF+</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau) requirement</td>
<td>Any</td>
</tr>
<tr>
<td class="label">Notable exclusion</td>
<td>None</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Primary Endpoint</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>CDR-SB</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>iADRS</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>CDR-SB</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>CDR-SB</td>
</tr>
<tr>
<td class="label">Solanezumab</td>
<td>CDR-SB</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Plaque Reduction (vs placebo)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>~70% SUVr reduction</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>84% of patients achieved plaque clearance</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>59% reduction</td>
</tr>
<tr>
<td class="label">Solanezumab</td>
<td>Minimal effect</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>ARIA-E (treatment)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>24.0%</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>25%</td>
</tr>
<tr>
<td class="label">Solanezumab</td>
<td>~2%</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Infusion reactions</td>
<td>~20% (mild/moderate)</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Falls</td>
<td>Slightly increased</td>
</tr>
<tr>
<td class="label">Discontinuation due to ARIA</td>
<td>~3%</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">FDA approved</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Meaningful clinical benefit</td>
<td>Yes (27% slowing)</td>
</tr>
<tr>
<td class="label">Robust plaque clearance</td>
<td>Yes (~70%)</td>
</tr>
<tr>
<td class="label">Biomarker modification</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Bi-weekly infusions</td>
</tr>
<tr>
<td class="label">Titration period</td>
<td>Yes (5 doses)</td>
</tr>
<tr>
<td class="label">Treatment discontinuation</td>
<td>Until progression</td>
</tr>
<tr>
<td class="label">Monitoring intensity</td>
<td>Moderate</td>
</tr>
</table>

Anti-amyloid monoclonal antibodies represent a transformative approach to disease-modifying therapy for Alzheimer's disease (AD). These therapeutics target various forms of amyloid-beta (Abeta) plaques and oligomers, aiming to remove pathological amyloid deposits and slow cognitive decline. Four antibodies have undergone extensive clinical development: [lecanemab](/entities/lecanemab), [donanemab](/entities/donanemab), gantenerumab, and solanezumab. This page provides a comprehensive comparison of their clinical trial designs, efficacy data, safety profiles, and patient selection criteria.

Mechanism of Action Comparison

Lecanemab

Lecanemab selectively binds to soluble Aβ protofibrils, which are believed to be the most toxic form of amyloid species. Protofibrils are intermediate aggregates that are more soluble than plaques but exhibit high neurotoxicity. By targeting protofibrils, lecanemab can neutralize soluble toxic species while also promoting clearance of deposited plaques[@van2023].

Donanemab

Donanemab preferentially binds to pyroglutamate-modified Aβ (N3pG-Aβ), an epitope that is enriched in deposited plaques rather than soluble monomers. This plaque-targeting mechanism leads to robust amyloid plaque removal through microglial-mediated phagocytosis[@sims2023].

Gantenerumab

Gantenerumab is a fully human IgG1 antibody that binds to aggregated Aβ in both oligomeric and fibrillar forms. It engages the Fcγ receptor pathway on [microglia](/cell-types/microglia-neuroinflammation), triggering antibody-mediated phagocytosis of amyloid plaques[@bateman2023].

Solanezumab

Solanezumab was designed to bind to the central domain of soluble Aβ monomers, promoting peripheral clearance of Aβ from the brain. However, its failure to meaningfully clear plaques or slow cognitive decline in multiple Phase 3 trials suggests that targeting soluble monomers alone is insufficient for clinical benefit[@salloway2023].

Clinical Trial Designs

Phase 3 Trials Overview

Patient Population Comparison

Key Design Differences

Tau Selection: Donanemab's TRAILBLAZER-ALZ 2 specifically enrolled patients with low-to-medium tau pathology, excluding those with high tau burden. This enrichment strategy may have contributed to its stronger efficacy signals.

Disease Stage: The A4 trial enrolled cognitively normal individuals with preclinical AD, making it unique as a secondary prevention trial. All other trials focused on early symptomatic disease.

Treatment Duration: CLARITY-AD and TRAILBLAZER-ALZ 2 were 18-month trials, while GRADUATE was 2 years.

Clinical Efficacy Data

Primary Endpoint Results

Amyloid Plaque Removal

Biomarker Changes

All antibodies that successfully removed amyloid plaques showed downstream biomarker effects:

Reduced CSF p-tau181: Consistent across lecanemab, donanemab, and gantenerumab trials, suggesting slowed tau pathology
Reduced CSF t-tau: Observed with amyloid clearance
Brain volume changes: Mixed results; some antibodies showed slower hippocampal atrophy, while others showed transient ARIA-related effects

Safety Profiles

ARIA is the most significant safety concern with anti-amyloid antibodies. It manifests as:

ARIA-E (edema): Fluid accumulation in the brain, visible on MRI as hyperintense T2/FLAIR signals
ARIA-H (hemorrhage): Microhemorrhages or superficial siderosis

Risk Factors for ARIA

[APOE](/proteins/apoe) ε4 carrier status: Higher risk, especially homozygous carriers

Age: Older patients may have higher risk

Baseline amyloid burden: Higher baseline plaque load associated with increased ARIA

Concurrent anticoagulation: Increased risk of ARIA-H

Management Strategies

Gradual titration: Lecanemab uses a titration schedule to reduce ARIA risk
Monitoring MRI: Required at baseline, Week 5, Week 13, and Week 25 for lecanemab
Dosing pause: For moderate-to-severe ARIA, dosing is paused until resolution
APOE testing: Recommended before treatment initiation

Other Adverse Events

Patient Selection Criteria

Approved Indications

Lecanemab (Leqembi):

Indicated for treatment of MCI due to AD or mild AD dementia
Confirmed presence of amyloid beta pathology
Patients with contraindication to MRI (e.g., implanted devices) should not receive treatment

Donanemab (Kisunla):

Indicated for treatment of early symptomatic AD (MCI due to AD or mild dementia)
Confirmed amyloid pathology
Should NOT be used in patients with:
Prior intracerebral hemorrhage
Uncontrolled seizures
Significant neurological disease other than AD

Practical Considerations

Cognitive Testing: Patients should have MMSE 20-30 (lecanemab) or 20-28 (donanemab)

Neuroimaging: MRI required for baseline and monitoring; PET for amyloid confirmation

APOE Status: APOE ε4 carriers have higher ARIA risk; consider in risk-benefit discussion

Anticoagulation: Caution with warfarin, DOACs; may need to hold during treatment

Treatment Setting: Requires infusion center access and MRI monitoring capability

Who May Benefit Most

Based on trial data, patients most likely to benefit:

Early disease stage: MCI due to AD shows best response
Lower tau burden: Donanemab specifically showed better outcomes in low-to-medium tau patients
Younger age: May have better clearance and fewer ARIA events
APOE ε4 non-carriers: Lower ARIA risk

Comparison Summary

Clinical Benefits

Practical Considerations

Future Directions

Combination Therapies

Anti-amyloid antibodies combined with anti-tau therapies
Combination with neurotrophic factors
Adjunct use with symptomatic medications

Biomarker-Driven Treatment

Using plasma biomarkers ([p-tau217](/biomarkers/p-tau-217), p-tau181) for patient selection
Tau PET for treatment response monitoring
Athome monitoring programs

Prevention Trials

AHEAD 3-45: Lecanemab in preclinical AD (NCT04468659)
Generation Study: CNP520 (BACE inhibitor) in preclinical AD

[Lecanemab (Leqembi) - Full Profile](/therapeutics/lecanemab)
[Donanemab (Kisunla) - Full Profile](/therapeutics/donanemab)
[Gantenerumab - Full Profile](/therapeutics/gantenerumab)
[Lecanemab CLARITY-AD Trial](/therapeutics/lecanemab-clarity-ad-trial)
[Donanemab TRAILBLAZER-ALZ 2 Trial](/therapeutics/donanemab-trailblazer-alz-2-trial)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Amyloid-Beta](/proteins/amyloid-beta)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[van Dyck et al., Lecanemab in Early Alzheimer's Disease (2023) (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Sims et al., Donanemab in Early Alzheimer's Disease (2023) (2023)](https://doi.org/10.1056/NEJMoa2304710)

[Bateman et al., Gantenerumab in Early Alzheimer's Disease (2023) (2023)](https://doi.org/10.1056/NEJMoa2305030)

[Salloway et al., A4 Study: Solanezumab in Preclinical Alzheimer's Disease (2023) (2023)](https://doi.org/10.1056/NEJMoa2305030)

[Cummings et al., Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease (2023) (2023)](https://doi.org/10.1001/jama.2023.13739)

[Budd Haeberlein et al., Lecanemab: Emergence of a New Treatment (2023) (2023)](https://doi.org/10.1001/jamaneurol.2023.0118)

[Pontecorvo et al., Donanemab: A Disease-Modifying Therapy (2024) (2024)](https://doi.org/10.1056/NEJMoa2404144)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — 0.58 · Target: FCGRT
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE
[Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — 0.66 · Target: AQP4

Related Analyses:

[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-anti-amyloid-antibody-clinical-trials

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-anti-amyloid-antibody-clinical-trials
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-021764df0a9b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-anti-amyloid-antibody-clinical-trials'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

216

Outgoing

230

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Anti-Amyloid Antibody Clinical Trials

Anti-Amyloid Antibody Clinical Trials

Overview

Anti-Amyloid Antibody Clinical Trials

Overview

Mechanism of Action Comparison

Lecanemab

Donanemab

Gantenerumab

Solanezumab

Clinical Trial Designs

Phase 3 Trials Overview

Patient Population Comparison

Key Design Differences

Clinical Efficacy Data

Primary Endpoint Results

Amyloid Plaque Removal

Biomarker Changes

Safety Profiles

Risk Factors for ARIA

Management Strategies

Other Adverse Events

Patient Selection Criteria

Approved Indications

Practical Considerations

Who May Benefit Most

Comparison Summary

Clinical Benefits

Practical Considerations

Future Directions

Combination Therapies

Biomarker-Driven Treatment

Prevention Trials

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Anti-Amyloid Antibody Clinical Trials

Anti-Amyloid Antibody Clinical Trials

Overview

Anti-Amyloid Antibody Clinical Trials

Overview

Mechanism of Action Comparison

Lecanemab

Donanemab

Gantenerumab

Solanezumab

Clinical Trial Designs

Phase 3 Trials Overview

Patient Population Comparison

Key Design Differences

Clinical Efficacy Data

Primary Endpoint Results

Amyloid Plaque Removal

Biomarker Changes

Safety Profiles

Amyloid-Related Imaging Abnormalities (ARIA)

Risk Factors for ARIA

Management Strategies

Other Adverse Events

Patient Selection Criteria

Approved Indications

Practical Considerations

Who May Benefit Most

Comparison Summary

Clinical Benefits

Practical Considerations

Future Directions

Combination Therapies

Biomarker-Driven Treatment

Prevention Trials

Related Pages

See Also

External Links

References

Related Hypotheses

💬 Discussion